An important phase III trial involving transplant-eligible patients with multiple myeloma compared bortezomib and dexamethasone (BzD) induction with the previous standard of care. BzD was associated with a higher overall response and a deeper response to therapy that translated to superior responses following high-dose therapy and autologous stem cell transplantation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Harousseau, J. L. et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005–01 phase III trial. J. Clin. Oncol. 28, 4621–4629 (2010).
Lahuerta, J. J. et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J. Clin. Oncol. 26, 5775–5782 (2008).
Wang, M. et al. CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplant. 45, 498–504 (2010).
O'Shea, D. et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant. 37, 731–737 (2006).
Majolino, I. et al. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo. Haematologica 84, 844–852 (1999).
Cavo, M. et al. Superior complete response rate and progression-free survival after autologous transplantation with up-front velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma [abstract]. Blood 112, a158 (2008).
Richardson, P. G. et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116, 679–686 (2010).
McCarthy, P. L. et al. Phase III intergroup study of lenalidomide (CC-5013) versus placebo maintenance therapy following single autologous stem cell transplant for multiple myeloma (CALGB 100104): initial report of patient accrual and adverse events [abstract]. Blood 114, a3416 (2009).
Attal, M. et al. Lenalidomide after autologous transplantation for myeloma: first analysis of a prospective, randomized study of the Intergroupe Francophone du Myelome (IFM 2005 02) [abstract]. Blood 114, a529 (2009).
Broyl, A. et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 11, 1057–1065 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P. Richardson is on advisory boards at Bristol-Myers Squibb, Celgene, Johnson & Johnson, Millennium Pharmaceuticals and Novartis. J. Laubach declares no competing interests.
Rights and permissions
About this article
Cite this article
Laubach, J., Richardson, P. Bortezomib and dexamethasone induction for multiple myeloma. Nat Rev Clin Oncol 8, 8–10 (2011). https://doi.org/10.1038/nrclinonc.2010.206
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2010.206
This article is cited by
-
New therapies and standard of care in oncology
Nature Reviews Clinical Oncology (2011)
